Bliss GVS Pharma Ltd's Q3FY25 Quarterly Results

Result Summary

• Bliss GVS Pharma Ltd reported a 1.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 9.5%.
• Its expenses for the quarter were up by 1.2% QoQ and 14.0% YoY.
• The net profit increased 0.4% QoQ and decreased 11.2% YoY.
• The earnings per share (EPS) of Bliss GVS Pharma Ltd stood at 2.3 during Q3FY25.

Financial Statments for Q3FY25

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Bliss GVS Pharma Ltd is a pharmaceutical company primarily engaged in the manufacturing and marketing of pharmaceutical formulations. The company is known for its diverse portfolio of products, which includes oral dosage forms, suppositories, and a range of other therapeutic segments. Bliss GVS Pharma Ltd operates in the pharmaceutical industry, which is characterized by rigorous regulatory standards and high levels of research and development. While the specific recent developments for the company are not available, the pharmaceutical industry as a whole has been experiencing increased demand due to growing healthcare needs globally.

Revenue

In the third quarter of FY25, Bliss GVS Pharma Ltd reported a total income of ₹225.68 crores, reflecting a 1.3% increase from the previous quarter (Q2FY25) where the total income was ₹222.72 crores. When compared to the same quarter in the previous fiscal year (Q3FY24), the total income has grown by 9.5%, up from ₹206.14 crores. This year-over-year growth indicates a positive trend in revenue generation for this period. The consistent quarter-over-quarter increase suggests a stable revenue performance over the recent quarters.

Profitability

The company's profit before tax in Q3FY25 was recorded at ₹36.42 crores, indicating a 2.0% increase from the previous quarter's figure of ₹35.71 crores. However, when compared to the same quarter last year, there is a 9.0% decline from ₹40.04 crores. After accounting for taxes, the profit after tax for Q3FY25 stood at ₹25.80 crores, a slight increase of 0.4% from Q2FY25 where it was ₹25.69 crores. On a year-over-year basis, the profit after tax decreased by 11.2% from ₹29.07 crores in Q3FY24. The earnings per share for Q3FY25 remained steady at ₹2.30, unchanged from the previous quarter but reflecting an 11.5% decline from ₹2.60 in the same quarter of the previous year.

Operating Metrics

The total expenses for Bliss GVS Pharma Ltd in Q3FY25 amounted to ₹189.26 crores, showing a 1.2% increase from Q2FY25, where expenses were ₹187.01 crores. Compared to Q3FY24, total expenses have risen by 14.0% from ₹166.09 crores. The tax expense for Q3FY25 was ₹10.62 crores, marking a 6.1% increase from the previous quarter's ₹10.01 crores, and a slight decrease of 3.2% from ₹10.97 crores in Q3FY24. These figures highlight the company's operating efficiency and cost management over the quarters. The financial data indicates a steady operating performance with minor fluctuations in tax expenditures.